Home/Filings/4/A/0001209191-12-047499
4/A//SEC Filing

Lyons Ruth Anne 4/A

Accession 0001209191-12-047499

CIK 0001013606other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 3:42 PM ET

Size

5.6 KB

Accession

0001209191-12-047499

Insider Transaction Report

Form 4/AAmended
Period: 2012-09-09
Lyons Ruth Anne
VP Global Marketing
Transactions
  • Award

    Common Stock

    2012-09-09$12.62/sh+28,944$365,27328,944 total
Footnotes (5)
  • [F1]25% vesting to occur upon the achievement of Nellix device revenue target for a month.
  • [F2]25% vesting to occur upon U.S. regulatory approval of Nellix device.
  • [F3]25% vesting to occur upon U.S. regulatory approval of Ventana device.
  • [F4]25% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.
  • [F5]100% cliff vesting to occur 9/9/2016 in the event milestones are not achieved.

Issuer

ENDOLOGIX INC /DE/

CIK 0001013606

Entity typeother

Related Parties

1
  • filerCIK 0001529074

Filing Metadata

Form type
4/A
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 3:42 PM ET
Size
5.6 KB